Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21392268 | 0.79 | HIF1A (0.37) | — | |
| SCHEMBL14932219 | 0.78 | P2RX4 (0.38) | — | |
| SCHEMBL21381185 | 0.78 | P2RX4 (0.33) | — | |
| SCHEMBL19794967 | 0.77 | JAK2 (0.37) | JAK2BTK | |
| SCHEMBL18222125 | 0.73 | LPL (0.51) | — | |
| SCHEMBL29662174 | 0.73 | LPL (0.51) | — | |
| SCHEMBL21895395 | 0.72 | P2RX4 (0.32) | — | |
| SCHEMBL31676557 | 0.72 | P2RX4 (0.35) | JAK2BTK | |
| SCHEMBL21392464 | 0.72 | ABL1 (0.37) | — | |
| SCHEMBL24422387 | 0.72 | P2RX4 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10886477-B2 | Iridium complex and organic electroluminescence device using the same | UDC IRELAND LIMITED (IE) | 2021-01-05 | — | — | US | disclosed |
| US-20190296251-A1 | IRIDIUM COMPLEX AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | LUMINESCENCE TECHNOLOGY CORPORATION (TW) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190296251-A1 | IRIDIUM COMPLEX AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME | IMPA1, LAGE3, OCIAD1 | JAK2 4751/4885BTK 1975/4885 |
| US-10886477-B2 | Iridium complex and organic electroluminescence device using the same | IMPA1, LAGE3, OCIAD1 | JAK2 4751/4885BTK 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.